Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.58 |
| ▸ | MAOA | P21397 | 2/20 | 0.49 |
| ▸ | MAOB | P27338 | 2/20 | 0.49 |
| ▸ | HNF4A | P41235 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.46 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21173600 | 0.85 | ESR2 (0.52) | ESR2MAOAMAOBSSTR2CXCR2 | |
| SCHEMBL1423587 | 0.83 | ESR2 (0.49) | ESR2SSTR2ALDH1A1HPGDHSD17B10 | |
| SCHEMBL9318618 | 0.83 | ESR2 (0.53) | ESR2MAOAMAOBHNF4AHDAC4 | |
| SCHEMBL18411431 | 0.82 | ESR2 (0.50) | ESR2MAOAMAOBALDH1A1HPGD | |
| SCHEMBL565466 | 0.82 | ESR2 (0.50) | ESR2HDAC4HDAC2HDAC8HDAC6 | |
| SCHEMBL1285671 | 0.81 | MAOA (0.50) | ESR2MAOAMAOBHNF4AHDAC4 | |
| SCHEMBL27895577 | 0.81 | ESR2 (0.69) | ESR2ALDH1A1HPGDGABRG2GABRB3 | |
| SCHEMBL29662886 | 0.81 | ESR2 (0.69) | ESR2MAOAMAOBALDH1A1HPGD | |
| SCHEMBL223 | 0.81 | ESR2 (0.69) | ESR2MAOAMAOBALDH1A1HPGD | |
| Water SCHEMBL3178714 | 0.81 | ESR2 (0.69) | ESR2MAOAMAOBALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011002408-A1 | NOVEL COMPOUNDS FOR TREATMENT OF NEURODEGENERATION ASSOCIATED WITH DISEASES, SUCH AS ALZHEIMER'S DISEASE OR DEMENTIA | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | WO | claimed |
| CN-116903493-A | Method for synthesizing polysubstituted o-phenylphenol compound through nucleophilic reaction ring opening of dibenzofuran | 华南理工大学 | 2023-10-20 | — | — | CN | disclosed |
| EP-1765408-B1 | POLYPEPTIDE PROTRACTING TAGS COMPRISING A TETRAZOLE MOIETY | NOVO NORDISK AS (DK) | 2015-12-09 | — | — | EP | disclosed |
| US-9061067-B2 | Polypeptide protracting tags | NOVO NORDISK A/S (DK) | 2015-06-23 | — | — | US | disclosed |
| EP-2289560-B1 | POLYPEPTIDE PROTRACTING TAGS COMPRISING A TETRAZOLE MOIETY | NOVO NORDISK AS (DK) | 2015-04-22 | — | — | EP | disclosed |
| US-20120088716-A1 | Polypeptide Protracting Tags | NOVO NORDISK A/S (DK) | 2012-04-12 | — | — | US | disclosed |
| EP-2292272-A2 | Polypeptide protracting tags comprising a tetrazole moiety | NOVO NORDISK A/S (DK) | 2011-03-09 | — | — | EP | disclosed |
| EP-2289560-A2 | Polypeptide protracting tags comprising a tetrazole moiety | NOVO NORDISK A/S (DK) | 2011-03-02 | — | — | EP | disclosed |
| WO-2011022337-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2011-02-24 | — | — | WO | disclosed |
| US-20090111730-A1 | Polypeptide protracting tags | NOVO NORDISK A/S (DK) | 2009-04-30 | — | — | US | disclosed |
| EP-1765408-A2 | POLYPEPTIDE PROTRACTING TAGS COMPRISING A TETRAZOLE MOIETY | NOVO NORDISK A/S (DK) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006005667-A2 | POLYPEPTIDE PROTRACTING TAGS COMPRISING A TETRAZOLE MOIETY | NOVO NORDISK A/S (DK) | 2006-01-19 | — | — | WO | disclosed |
| EP-1611091-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004089885-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-10-21 | — | — | WO | disclosed |
| JP-2003119175-A | TERT-AMYLOXYHALOGENOBENZENE COMPOUND, METHOD FOR PRODUCING THE SAME, TERT-AMYLOXYCYANOBIPHENYL COMPOUND, METHOD FOR PRODUCING THE SAME AND METHOD FOR PRODUCING CYANOHYDROXYBIPHENYL COMPOUND | HOKKO CHEM IND CO LTD | 2003-04-23 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088716-A1 | Polypeptide Protracting Tags | VIP, FGB, NPPA | ESR2 2026/4885MAOA 4556/4885MAOB 4235/4885 |
| US-20090111730-A1 | Polypeptide protracting tags | LNPEP, FGB, ENPEP | ESR2 3061/4885MAOA 3951/4885MAOB 3926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.